Is Johnson & Johnson Stock Ready For A MedTech Stall?

For questions about this article or underlying research, email help@trefis.com.

What if MedTech, the smaller of Johnson & Johnson’s (JNJ) two businesses, stopped growing? On the October 13, 2026 call, management said MedTech’s third-quarter growth fell short of its own expectations, and the topic came up again during the question session. At 29.5 times earnings compared to 23.0 for the S&P 500, the stock’s premium valuation implies elevated market expectations for continued growth. So how close is MedTech to a stall already?

How Fast Is Johnson & Johnson’s MedTech Business Growing?

MedTech sales grew 2.5% in the third quarter of fiscal 2026, trailing the 7.9% posted by Innovative Medicine. Surgery sales fell 1%, weighed down by headwinds in China, disruption in the Middle East, and an internal portfolio overhaul. Geographically, growth was almost entirely domestic: U.S. sales rose 4.8%, while international sales remained essentially flat at 0.1%.

What Would A MedTech Stall Cost Johnson & Johnson (JNJ)?

A stall would cost little in sales. MedTech brought in $8.6 billion of the $25.4 billion Johnson & Johnson sold in the third quarter, accounting for about a third of the total. The unit’s growth that quarter amounted to roughly $0.2 billion of extra sales, and a stall would take that away. The company as a whole still grew 6%, with the larger and faster-growing medicines business providing most of that growth.

A stall would matter more to the premium that holders pay for growth. Management says it has a clear path to double-digit growth by the end of the decade, and on the call it said that target does not assume any acquisitions. That growth has to come from businesses Johnson & Johnson already owns, and MedTech is one of only two. MedTech is also set to lose orthopedics, which Johnson & Johnson plans to separate by mid-2027.

When Johnson & Johnson is a large share of what you own, one outcome can decide much of your plan. See how to protect a concentrated position.

Johnson & Johnson Can Lean On Medicines And Cash

Innovative Medicine sold $16.8 billion in the third quarter, and management said oncology sales within it grew about 17%. That is the business setting the company’s pace while MedTech lags.

Johnson & Johnson also has the cash to wait for MedTech to recover. Free cash flow was $22.2 billion over the four quarters to June 28, 2026. Management said the third quarter added more than $6 billion and still expects $21 billion for the full year. Operating income over the same four quarters was 25.9 times interest expense, meaning interest costs are small next to the company’s profit. A stall would slow Johnson & Johnson’s growth without straining its finances. The business is ready for a MedTech stall, but the stock is less so, because a stall would test the growth that holders pay a premium for.

How Will You Know If MedTech Is Recovering?

Management expects fourth-quarter U.S. approval for VARIPULSE Pro, a MedTech product already approved in Japan. When Johnson & Johnson reports in January 2027, MedTech’s sales growth outside the U.S. is the number to watch.

Is Too Much Of Your Wealth Riding On One Stock?

Johnson & Johnson holders are waiting on an outcome they do not control. When one position grows into a large part of your wealth, a sharp fall can hurt your whole plan, and selling to spread the money out can bring a large tax bill. Our partner advisory firm offers a free strategy review of ways to protect a concentrated position and unwind it with less tax.

Request A Free Strategy Review

Spot an error or want more like this? Tell us in 10 seconds.